New drug trial tests hope for Hard-to-Treat tumors
NCT ID NCT05077384
Summary
This study tested a drug called surufatinib in Japanese patients with advanced neuroendocrine tumors that had stopped responding to standard treatments. The first part checked the drug's safety and the best dose, while the second part measured how well it shrank tumors. A total of 36 patients took the oral drug daily in 28-day cycles.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Centre
Nagoya, 464-8681, Japan
-
Fukuoka Sanno Hospital
Fukuoka, 814-0001, Japan
-
Hokkaido University Hospital
Sapporo, 060-8648, Japan
-
Kagawa University Hospital
Kagawa, 761-0793, Japan
-
Kansia Electric Power Hospital
Osaka, 553-0003, Japan
-
Kyorin University Hospital
Mitaka, 181-8611, Japan
-
Kyoto University Hospital
Kyoto, 606-8507, Japan
-
Kyushu University Hospital
Fukuoka, 812-0054, Japan
-
National Cancer Centre Hospital
Tokyo, 104-004, Japan
-
National Cancer Centre Hospital East
Kashiwa-shi, 277-8577, Japan
-
Tohoku University Hospital
Sendai, 890-8574,, Japan
-
Yokohama City University Hospital
Yokohama, 236-0004, Japan
Conditions
Explore the condition pages connected to this study.